Table A1.
Treatment Cycle Delays and Dose Reductions
| Cycle or Dose Variable | No. (%) of Patients |
|
|---|---|---|
| Trabectedin (n = 340) | Dacarbazine (n = 155) | |
| Total with at least two cycles | 298 (88) | 125 (81) |
| Cycle delay | ||
| Yes | 193 (57) | 62 (40) |
| No | 105 (31) | 63 (41) |
| No. of cycle delays | ||
| 1 | 96 (28) | 35 (23) |
| 2 | 37 (11) | 13 (8) |
| 3 | 27 (8) | 8 (5) |
| 4 | 12 (4) | 1 (1) |
| ≥ 5 | 21 (6) | 5 (3) |
| Dose reduction | ||
| Yes | 119 (35) | 15 (10) |
| No | 179 (53) | 110 (71) |
| No. of dose reductions | ||
| 1 | 83 (24) | 13 (8) |
| 2 | 36 (11) | 2 (1) |
NOTE. Cycle delays and dose reductions were tabulated for patients who received at least two cycles of treatment.